Dr. Jeremy Parker obtained his BSc in Chemistry from Imperial College, University of London in 1994. He then moved to the University of Oxford, completing a DPhil investigating biomimetic Diels-Alder reactions with Professor Sir J E Baldwin. He joined AstraZeneca in 1999 and has held various roles including Technical Sourcing Manager, Analytical Chemistry Team Manager and Process Chemistry Team Manager. In 2013 he took over responsibility for all Antibody Drug Conjugate Payload projects within AstraZeneca, and is currently a Principal Scientist, based at Macclesfield in the United Kingdom.
Challenges and Opportunities in the Synthesis of Antibody Drug Conjugate Payloads
Monday, 2 March 2015 at 10:45
Add to Calendar ▼2015-03-02 10:45:002015-03-02 11:45:00Europe/LondonChallenges and Opportunities in the Synthesis of Antibody Drug Conjugate Payloads Current Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
In this presentation, process
chemistry including route design and process design will be discussed for
preparation of Antibody Drug Conjugates Payloads. Further, this talk will also
explain how principal component analysis can be used to analyse known lists of
available cytotoxic molecules which promotes the use of payloads that target
chemotherapeutic mechanisms as well as identifying those which are structurally
simple and commercially available.
Add to Calendar ▼2015-03-02 00:00:002015-03-03 00:00:00Europe/LondonCurrent Trends in Antibody Drug ConjugatesCurrent Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-03-02 10:45:002015-03-02 11:45:00Europe/LondonChallenges and Opportunities in the Synthesis of Antibody Drug Conjugate Payloads Current Trends in Antibody Drug Conjugates in Bangalore, IndiaBangalore, IndiaSELECTBIOenquiries@selectbiosciences.com
